OK to ENTER
11/30/05

AMENDMENT TO THE CLAIMS

The present amendment amends claim 55. According to 37 C.F.R. § 1.121(c), after entry of the present amendment, the following claims are in the case:

Claims 1-3 cancelled

4. (Previously Presented) The kit of claim 52, wherein said targeting agent-therapeutic agent construct comprises at least a first anti-aminophospholipid antibody that binds to phosphatidylethanolamine, or antigen-binding fragment thereof.

5. (Previously Presented) The kit of claim 4, wherein said targeting agent-therapeutic agent construct comprises at least a first IgG or IgM anti-aminophospholipid antibody that binds to phosphatidylethanolamine.

6. (Previously Presented) The kit of claim 4, wherein said targeting agent-therapeutic agent construct comprises at least a first scFv, Fv, Fab', Fab or $F(ab')_2$ antigen-binding fragment of an anti-aminophospholipid antibody that binds to phosphatidylethanolamine.

7. (Previously Presented) The kit of claim 4, wherein said targeting agent-therapeutic agent construct comprises at least a first recombinant anti-aminophospholipid antibody that binds to phosphatidylethanolamine, or antigen-binding fragment thereof.

8. (Previously Presented) The kit of claim 4, wherein said targeting agent-therapeutic agent construct comprises at least a first human, humanized or part-human chimeric anti-

aminophospholipid antibody that binds to phosphatidylethanolamine, or antigen-binding fragment thereof.

9. (Previously Presented) The kit of claim 4, wherein said targeting agent-therapeutic agent construct comprises at least a first monoclonal anti-aminophospholipid antibody that binds to phosphatidylethanolamine, or antigen-binding fragment thereof.

10. (Previously Presented) The kit of claim 52, wherein said targeting agent-therapeutic agent construct comprises at least a first aminophospholipid binding protein that binds to phosphatidylethanolamine or an aminophospholipid-binding fragment thereof.

Claims 11 and 12 cancelled

13. (Previously Presented) The kit of claim 10, wherein said targeting agent-therapeutic agent construct comprises at least a first kininogen or a phosphatidylethanolamine-binding fragment thereof.

14. (Previously Presented) The kit of claim 52, wherein said targeting agent-therapeutic agent construct comprises at least a first anticellular or cytotoxic agent.

15. (Original) The kit of claim 14, wherein said targeting agent-therapeutic agent construct comprises at least a first gelonin, ricin A chain or deglycosylated ricin A chain.

16. (Previously Presented) The kit of claim 52, wherein said targeting agent-therapeutic agent construct comprises at least a first coagulant.

17. (Original) The kit of claim 16, wherein said targeting agent-therapeutic agent construct comprises at least a first Tissue Factor, dimeric Tissue Factor, trimeric Tissue Factor, polymeric Tissue Factor, mutant Tissue Factor, truncated Tissue Factor or a Tissue Factor derivative.

18. (Previously Presented) The kit of claim 52, wherein said targeting agent-therapeutic agent construct comprises an antibody that binds to phosphatidylethanolamine, or antigen binding fragment thereof, wherein said antibody or antigen binding fragment thereof is directly or indirectly attached to truncated Tissue Factor.

19. (Previously Presented) The kit of claim 52, wherein said kit comprises at least a first pharmaceutically acceptable formulation suitable for intravenous administration.

Claims 20-24 cancelled

25. (Previously Presented) The kit of claim 52, wherein said at least a first targeting agent-therapeutic agent construct and said at least a second anti-cancer agent are comprised within a single pharmaceutical composition.

26. (Previously Presented) The kit of claim 52, wherein said at least a first targeting agent-therapeutic agent construct and said at least a second anti-cancer agent are comprised within distinct pharmaceutical compositions.

27. (Previously Presented) The kit of claim 52, wherein said at least a second anti-cancer agent is a chemotherapeutic agent, radiotherapeutic agent, anti-angiogenic agent or apoptosis-inducing agent.

28. (Previously Presented) The kit of claim 52, wherein said at least a second anti-cancer agent is an antibody-therapeutic agent construct comprising a second targeting antibody, or antigen-binding fragment thereof, that binds to a surface-expressed, surface-accessible or surface-localized component of a tumor cell, tumor stroma or tumor vasculature; wherein said targeting antibody or fragment thereof is operatively linked to a therapeutic agent.

29. (Original) The kit of claim 28, wherein said second targeting antibody, or antigen-binding fragment thereof, binds to a surface-expressed, surface-accessible, surface-localized, cytokine-inducible or coagulant-inducible component of intratumoral blood vessels of a vascularized tumor.

30. (Original) The kit of claim 29, wherein said second targeting antibody, or antigen-binding fragment thereof, binds to a component of intratumoral vasculature selected from the group consisting of an aminophospholipid, endoglin, a TGFβ receptor, E-selectin, P-selectin, VCAM-1, ICAM-1, PSMA, a VEGF/VPF receptor, an FGF receptor, a TIE, $\alpha_v\beta_3$ integrin, pleiotropin, endosialin, an MHC Class II protein, VEGF/VPF, FGF, TGFβ, a ligand that binds to a TIE, a tumor-associated fibronectin isoform, scatter factor/hepatocyte growth factor (HGF), platelet factor 4 (PF4), PDGF and TIMP.

31. (Original) The kit of claim 28, wherein said second targeting antibody, or antigen-binding fragment thereof, is operatively linked to gelonin, deglycosylated ricin A chain, Tissue Factor, truncated Tissue Factor or to an antibody, or antigen-binding fragment thereof, that binds to Tissue Factor or truncated Tissue Factor.

32. (Previously Presented) The kit of claim 52, wherein said kit further comprises a targeting agent-detectable agent construct that comprises a second targeting agent that binds to phosphatidylethanolamine operatively attached to a detectable agent.

Claims 33-42 cancelled

43. (Previously Presented) In combination, biologically effective amounts of:

(a) a first composition comprising at least a first anti-cancer agent, wherein said at least a first anti-cancer agent is at least a first targeting agent-therapeutic agent construct that comprises at least a first therapeutic agent operatively attached to at least a first targeting agent that binds to phosphatidylethanolamine;

(b) a second composition comprising a targeting agent-detectable agent construct that comprises a detectable agent operatively attached to a second targeting agent that binds to phosphatidylethanolamine; and

(c) at least a second anti-cancer agent other than said at least a first targeting agent-therapeutic agent construct.

44. (Previously Presented) The kit of claim 43, wherein the targeting agent of said at least a first targeting agent-therapeutic agent construct and the targeting agent of said targeting agent-

detectable agent construct are anti-aminophospholipid antibodies that bind to phosphatidylethanolamine, or antigen-binding fragments thereof, obtained from the same antibody preparation or antibody-producing hybridoma.

45. (Previously Presented) The combination of claim 43, wherein said first composition is a pharmaceutical composition.

46. (Previously Presented) The combination of claim 43, wherein said second composition is a pharmaceutical composition.

47. (Previously Presented) The combination of claim 43, wherein said at least a second anti-cancer agent is admixed with said at least a first targeting agent-therapeutic agent construct to form a therapeutic cocktail.

48. (Previously Presented) The combination of claim 43, wherein said at least a second anti-cancer agent is comprised within a composition distinct from said at least a first targeting agent-therapeutic agent construct.

Claim 49 cancelled

50. (Previously Presented) The kit of claim 52, wherein said kit comprises at least a first pharmaceutically acceptable liposomal formulation.

Claim 51 cancelled

52. (Previously Presented) A kit comprising, in a pharmaceutically acceptable form, therapeutically effective amounts of:

(a) at least a first anti-cancer agent, wherein said at least a first anti-cancer agent is at least a first targeting agent-therapeutic agent construct that comprises at least a first targeting agent operatively attached to at least a first therapeutic agent, wherein said at least a first targeting agent binds to phosphatidylethanolamine expressed on the luminal surface of blood vessels of a vascularized tumor; and

(b) at least a second anti-cancer agent other than said at least a first targeting agent-therapeutic agent construct.

53. (Previously Presented) A kit comprising, in a pharmaceutically acceptable form, therapeutically effective amounts of:

(a) at least a first anti-cancer agent, wherein said at least a first anti-cancer agent is at least a first targeting agent-therapeutic agent construct that comprises at least a first targeting agent operatively attached to at least a first therapeutic agent, wherein said at least a first targeting agent binds to phosphatidylethanolamine on the luminal surface of blood vessels of a vascularized tumor; and

(b) at least a second anti-cancer agent other than said at least a first targeting agent-therapeutic agent construct; wherein said at least a second anti-cancer agent:

(i) increases phosphatidylethanolamine expression in the endothelium of said blood vessels of said vascularized tumor or injures or induces apoptosis in the endothelium of said blood vessels of said vascularized tumor; or

(ii) kills tumor cells of said tumor or is an anti-angiogenic agent that inhibits metastasis of tumor cells.

54. (Previously Presented) The kit of claim 53, wherein said at least a second anti-cancer agent increases phosphatidylethanolamine expression in the endothelium of said blood vessels of said vascularized tumor or injures or induces apoptosis in the endothelium of said blood vessels of said vascularized tumor.

55. (Currently Amended) The ~~method~~ kit of claim 54, wherein said at least a second anti-cancer agent is taxol, vincristine, vinblastine, neomycin, a combretastatin, a podophyllotoxin, TNF-α, angiostatin, endostatin, vasculostatin, an $\alpha_v\beta_3$ antagonist, a calcium-flux inducing agent, a calcium ionophore, H_2O_2, thrombin, an inflammatory cytokine or interleukin-4.

56. (Previously Presented) The kit of claim 53, wherein said at least a second anti-cancer agent kills tumor cells of said tumor or is an anti-angiogenic agent that inhibits metastasis of tumor cells.

57. (Previously Presented) The kit of claim 56, wherein said at least a second anti-cancer agent is an anti-tumor cell immunoconjugate, a chemotherapeutic agent or an anti-angiogenic agent.